Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome

High Blood Pressure and Cardiovascular Prevention

Volumn 23, Issue 3, 2016, Pages 175-179

  Seravalle, Gino ^a   Grassi, Guido ^b,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Baroreflex; Insulin resistance; Leptin; Metabolic syndrome; Obesity; Sympathetic nervous system

Indexed keywords

INSULIN; LEPTIN; BIOLOGICAL MARKER;

ABDOMINAL OBESITY; ADRENERGIC SYSTEM; ARTICLE; CARDIOVASCULAR RISK; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; INSULIN RESISTANCE; PROGNOSIS; RISK FACTOR;

ANIMALS; BAROREFLEX; BIOMARKERS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME; OBESITY, ABDOMINAL; OXIDATIVE STRESS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84987653392     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-016-0137-4     Document Type: Article

References (44)

1. Ncep-Atp III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). J Am Med Ass. 2001;285:1486–2497.
2. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817–22.
3. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138:24–32.
4. Grassi G, Seravalle G, Dell’Oro R, Quarti Trevano F, Bombelli M, Scopelliti F, Facchini A, Mancia G. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761–9.
5. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560–5.
6. Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514–20.
7. Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.
8. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzales-Sanchez JL, Seclen S, Villena A, Gonzales-Villapando C, Williams K, Haffner SM. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of metabolic syndrome in non diabetic subjects. Diabetes Care. 2006;29:685–91.
9. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. Metabolic syndrome: prevalence and association risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–36.
10. Poyrazoglu S, Bas F, Darendeliler F. Metabolic syndrome in young people. Curr Opin Endocrinol Diabetes Obes. 2014;21:56–63.
11. Alberti KG, Zimmet P, Shaw J, For the IDF Epidemiology Task Force Consensus Group. Metabolic syndrome: a new world-wide definition. Lancet. 2005;366:1059–1062.
12. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis. 2004;14:228–32.
13. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17:319–26.
14. Siani A, Strazzullo P. Tackling the genetic bases of metabolic syndrome: a realistic objective? Nutr Metab Cardiovasc Dis. 2006;16:309–12.
15. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, Hlatky MA, Fortmann SP. Metabolic syndrome and early-onset coronary artery disease. Is the whole greater than its parts? J Am Coll Cardiol. 2006;48:1800–7.
16. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–81.
17. Landsberg L. Diet, obesity and hypertension: an hypothesis involving the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081–90.
18. Young JB, Macdonald IA. Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord. 1992;16:959–67.
19. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension. 1991;17:669–77.
20. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–3.
21. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423–9.
22. Grassi G, Dell’Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effects of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensive. J Hypertens. 2004;22:2363–9.
23. Alvarez GE, Ballard TP, Beske SD, Davy KP. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol. 2004;287:H414–8.
24. Huggett RJ, Burns J, Makintosj AF, Mary DA. Sympathetic neural activation in non diabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847–52.
25. Grassi G, Dell’Oro R, Quarti Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359–65.
26. Grassi G, Seravalle G, Quarti Trevano F, Scopelliti F, Dell’Oro R, Bolla GB, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension. 2007;49:535–41.
27. Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, Scherrer U. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92:147–54.
28. Gudbjornsdottir S, Friberg P, Elam M, Attvall S, Lonnroth P, Wallin BG. The effects of metformin and insulin on sympathetic nerve activity, norepinehrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood press. 1994;3:394–403.
29. Shlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine uptake, and angiotensin neuromodulation. Hypertension. 2004;43:169–75.
30. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brandt DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21:618–23.
31. Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F, Esler M. Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab. 2004;286:E744–52.
32. Straznicky NE, Lambert E, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998–6005.
33. Zha JM, Di WJ, Zhu T, Xie Y, Yu J, Liu J, Chen P, Ding G. Comparison of gene transcription between subcutaneous and visceral adipose tissue in Chinese Adults. Endocr J. 2009;56:935–44.
34. Mark AL. Selective leptin resistance revisited. Am J Physiol Endocrinol Metab. 2013;305:R566–81.
35. Grassi G, Seravalle G, Colombo M, Bolla GB, Cattaneo BM, Cavagnini F, Mancia G. Body weight reduction, sympathetic nerve traffic and arterial baroreflex in obese normotensive humans. Circulation. 1998;97:2037–42.
36. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation. 1999;99:1183–9.
37. Grassi G, Facchini A, Quarti Trevano F, Dell’Oro R, Arenare F, Tana F, Bolla GB, Monzani A, Robuschi M, Mancia G. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46:321–5.
38. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol Endo Metab. 1992;262:E763–78.
39. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M. Angiotensin II blunts, while angiotensin converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exper Pharmacol Physiol. 1999;26:797–802.
40. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–7.
41. Prabhakar NR, Fields RD, Baker T, Fletcher EC. Intermittent hypoxia: cell to system. Am J Physiol. 2001;281:L524–8.
42. Belaidi E, Joyeux-Faure M, Ribout C, Launois SH, Levy P, Godin Ribout D. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in animal model of obstructive sleep apnea. J Am Coll Cardiol. 2009;53:1309–17.
43. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.
44. Bruno RM, Ghiadoni L, Seravalle G, Dell’Oro R, Taddei S, Grassi G. Sympathetic regulation of vascular function in health and disease. Front Physiol. 2012;3:284.